{"name":"Oxular Limited","slug":"oxular-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOTHNDR2RoWGUwU3lJeHRocVBKaW5WQ09zM2xwWEQzS1JTMndGcFhUcDV0OUpsNTBycEgwVUY3YUJjZ01EOEJJOXdzaER6RF9yQncwc2txQmlGUnktdXBzNXFWVFhpREthbmlabF9vd0JCYTdyYkJnTUxaNkFsbl9tOGt0Qko4TWRmbjh0QnhQa1AtVkRESktTR2lR?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Emerging Growth Patterns Driving Expansion in the Anterior Uveitis Market - openPR.com","headline":"Emerging Growth Patterns Driving Expansion in the Anterior Uveitis Market","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-23","type":"pipeline","source":"prnewswire.com","summary":"Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Sur","headline":"Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQazRiU2QySU9EWFpxczI2alZmOVliSEdRUi14SFJIMzlwcnljbHNzU0NQZGhkOWJxRkxlU2xjYzhYZ3BZLV9yTjFrTENadWFjRVlJM1lPckpISUw2NWozZDFzeVZsRmVJdHNUWWExYlVpTzdFUzQ2NzUzTF9LazV3REtQNkdhNnRicnplNTYxaThLZE50TmVRY3B4Z1NpZWVtOWl5NmFUa2RKeUJicXloY2RRVVZGS2ttc3o1RGtB?oc=5","date":"2026-02-17","type":"regulatory","source":"Fierce Pharma","summary":"Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Eylea, but investors balk - Fierce Pharma","headline":"Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Eylea, but investors balk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPcGRVemtaSWRYcFF2dlJCODZyWVlURWFYZ1o0WmtjQjRrazk3OGIyOHZUMDVqdGRqRF9oclNYNUtVT0NBbTFHSEJSTFI0ZkZsQkM1YkJQSWxrcENFS3Fyam52TWkyMG9OUjllV1B5UVR1eVFOcUhyVEJCWFJkYlUtZk1obVlKWHBm?oc=5","date":"2026-01-26","type":"earnings","source":"Yahoo Finance","summary":"A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack - Yahoo Finance","headline":"A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgNBVV95cUxPdUtoUkZscEVqbV9xeFdmTUZ6VzJRbGUwWmx1SDVyZmtYTl9CQ3BQaVFQd21mZ0RYa3RDNmVLc1BPNEVIOWRvNzc4a25SVjNUT21VOWd5WXNRYkFOYWFxTjNjb2F0ZGl0akxWVmtVNlA3eDAtVnc4MHRyZFhBa1hqbDNPa2N2LVlMQ2QxOU9vd0VHNUpXLUZTRi1uWDhGM0RnenJ0bm5jREQyMTZPdXJVcWRUaWtDVDhqRDV0VHp2aWZzV3p4V3QwZC0zbWFSaElUWHF6eWNhRTBNbVVHTXhZdjU3Sk9GZU9rQzZ4eFlsZzJ2U3NMaFpqNDYyalNxdV90OWdjNmxlZ2FIYklOQTM2NGZKUEtKN1piVENqYnNlb2diMmpMSGFfcVFNUUFDN2pGNFcxcVFVdjgtXzI1Q0lJbmpaV1JXMjJIaGstR0NTSE1YRTFLVlhNSHVlT0kycmp0clpId0Y2S0g3Tjh5MjZpbnJseXpfV3BOMlFzX3R1Rk1rUl9XZWJRcDZtRFR4NER1Vmc?oc=5","date":"2026-01-12","type":"pipeline","source":"prnewswire.com","summary":"Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and P","headline":"Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOLTZoZzNhWm5OR1UxQWpCT044Y0Z4STZrci1WLUpZd0lqZHQ1ZmVvUk1XLUt3ejhVREJ1aVlGYnhsQ0xYWjByLVAxVENia2VlWVJTeUhQMmRod0M5dVpxX3hQQXRMdXhiY2VKemZKczRjTDR4Rl9iNjN5Zk5NbWVJV29ZN0tYVC1TT2dRMmR0S0E4eWRzczVGZVNNcFF4Wndpb243TEpkTGlEdjllaGRSTGNJUC1iYkU3MmdvM2pHbnZ0NTNFd3Zv?oc=5","date":"2025-12-16","type":"deal","source":"BioCentury","summary":"RTW leans into NewCo model with GenSci deal for ocular autoimmune therapy: Deals Report - BioCentury","headline":"RTW leans into NewCo model with GenSci deal for ocular autoimmune therapy: Deals Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPU0Fjc1FyN0cxLTZtVUkzUlZESGt6LVBhR2NhbGVUWmQwSGxwVG9uZ1V1UnBhamh1VF9zTlk5aDktZnN2TVpDTnBfOFpkSzVFTjl1U1BXdHplcG5PMWhIQlhWdWNkUnVrTG9RamtuLUdtb21Qdks0a1EtNXN1MzVidjdBaXpka0lOZF9uWm81NjVVQTJTazVFMjN4bnk0Q1lfcklrN2toalRrUDJlZUZ4UmtxZVRMMHRzbkpleHIyOGM5M3BZRllYR2hlMjNSOS1rcUhsN3Y4QU1GSUF1?oc=5","date":"2025-07-17","type":"pipeline","source":"Proactive financial news","summary":"OKYO Pharma bolsters ocular pain program with $1.9M non-dilutive financing - Proactive financial news","headline":"OKYO Pharma bolsters ocular pain program with $1.9M non-dilutive financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOcUNuTXVyUHVIMUs2T1VGVFNHVXdvTGFGcDJRLXVhSmhkTWNJMHB6SFl2QzRrRGk1NHM3b2trcjVpLW9GN3ZGZDZicEFBRi1rdVZyY05aVWd6WEtUY0tlUEtveVI4SlJVNTJnUVJ2ejJHNVVKaUhadWFVUkJGc0pfX0VKLTQ5X2t0NHkwSW1MOU1STmxDNmllZWM4NzZyOVgydloxaWRUWXM0UEc1RTVJN0I1WlAySGpsTlJuYk1yRjBzem5XN0Y2Z1RmaHNpZlZhVXBjbW8zTmw?oc=5","date":"2025-05-29","type":"deal","source":"BioSpectrum Asia","summary":"Taiwan's Formosa Pharma inks deal with Adalvo for treatment of ocular inflammation and pain - BioSpectrum Asia","headline":"Taiwan's Formosa Pharma inks deal with Adalvo for treatment of ocular inflammation and pain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNWFVxM3g2ZktXaTJJOFpLUXMzYzRybWRXU3JqS1ZuOWlhX2JKc1luaVVKMG1GZlREQ2sxSVVaeWpLY0pRUTN0dDBUMGltcGhmR3p3QURnRDRLeGhfMUxRc2dmaVBGc2c4R0V1d0lMNkVrcTVaNV85X3BRdi0zTFlCREp2c2l1TU9LRGEzdFdHdVBKNUx1ZVdzS296N2s0bmhLeVJKYktPdWJJOE94MHRnS2wwUk9TQQ?oc=5","date":"2025-01-06","type":"deal","source":"Ophthalmology Times Europe","summary":"Regeneron acquires UK biotech company Oxular, broadening retina portfolio - Ophthalmology Times Europe","headline":"Regeneron acquires UK biotech company Oxular, broadening retina portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPTkdSNjBibjlva0s2elhVMTRCTXpQOXVEUFBjdE9QWXh2SFkzeFdzeEViSEd5dFlCdjljeGtGWkxyek9Rd3luNVhKeTd5b2t4RTFlQUZwZjR1aW1mdldlVXlFWEYzYmtZdGhpVXZlVUlVYlhyLU9HdlVITk10VEhXX0c1U3BWQy1LQWltXzBkT3NBTHc0cXFKOEYzY2s2dW9ZODhEbkE5S1JwUQ?oc=5","date":"2025-01-06","type":"pipeline","source":"Eyes On Eyecare","summary":"Regeneron reportedly purchases British biotech Oxular - Eyes On Eyecare","headline":"Regeneron reportedly purchases British biotech Oxular","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxORV8zelZlRnNfZHRxLVlaYXpaMERKZzdoZ3MybGY5a2JCNlFXQ0ZGMFFuR2xqUnYxQlhXR1JjUHdHV0plWjFwQU5fd0xhSTBveVd0LU9xalBIQ1A3OVk4VGpmWG5lRWdIX1UzOHZPQUVFMjBhMU5iYVFhNmtrb01FTlI1NC1jWV83UUg3a1FJQjQ2QnlvWjFFclNBQ295eHhjMTdiMG42cnpldGFuSkYwYUV4dDBGaHU1MXc?oc=5","date":"2025-01-02","type":"deal","source":"Fierce Biotech","summary":"Regeneron acquires UK biotech, adding Oxular's eye disease delivery tech to portfolio - Fierce Biotech","headline":"Regeneron acquires UK biotech, adding Oxular's eye disease delivery tech to portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE10RU1jZ0doWm5MMHZvZWJvV3Yxei1iUkpqMF9naHlIZ3lIS3pFNlFrWEVBandUMDM4YjBpeTNIeURxYnNvNURfaTR2eGwwc2tOTDI4?oc=5","date":"2025-01-02","type":"deal","source":"FirstWord Pharma","summary":"Regeneron buys UK-based eye drug developer Oxular - FirstWord Pharma","headline":"Regeneron buys UK-based eye drug developer Oxular","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}